|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 11400 Rockville Pike |
Address2 |
|
| City | Rockville |
State | MD |
Zip Code | 20852 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104864-12
|
||||||||
|
6. House ID# 440290001
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kelly Corredor |
Date | 4/18/2025 6:45:22 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS:
Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria.
Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders.
Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products.
Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis.
Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation.
Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing.
Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule.
Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction.
Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes.
Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field.
Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes.
Lobbied to raise federal alcohol taxes
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS:
Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria.
Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders.
Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products.
Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis.
Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation.
Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing.
Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule.
Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction.
Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes.
Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field.
Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes.
Lobbied to raise federal alcohol taxes
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS:
Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria.
Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders.
Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products.
Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis.
Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation.
Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing.
Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule.
Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction.
Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes.
Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field.
Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes.
Lobbied to raise federal alcohol taxes
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS:
Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria.
Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders.
Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products.
Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis.
Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation.
Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing.
Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule.
Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction.
Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes.
Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field.
Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes.
Lobbied to raise federal alcohol taxes
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS:
Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria.
Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders.
Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products.
Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis.
Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation.
Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing.
Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule.
Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction.
Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes.
Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field.
Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes.
Lobbied to raise federal alcohol taxes
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS:
Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria.
Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders.
Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products.
Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis.
Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation.
Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing.
Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule.
Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction.
Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes.
Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field.
Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes.
Lobbied to raise federal alcohol taxes
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |